Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

被引：0
|
作者：
Park, Keunchil
Lee, Jong-Seok
Lee, Ki Hyeong
Kim, Joo-Hang
Min, Young Joo
Cho, Jae Yong
Han, Ji-Youn
Kim, Bong-Seog
Kim, Jin-Soo
Lee, Dae Ho
Kang, Jin Hyoung
Cho, Eun Kyung
Jang, In-Jin
Jung, Jina
Kim, Hyo-Yeon
Sin, Hui Jung
Son, Jeewoong
Woo, Jong Soo
Kim, Dong-Wan
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol, Seoul, South Korea
[2] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul Natl Unvers,Bundang Hosp, Soengnam, South Korea
[3] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[4] Yonsei Canc Ctr, Seoul, South Korea
[5] Ulsan Univ Hosp, Dept Med, Ulsan, South Korea
[6] Gangnam Severance Hosp, Seoul, South Korea
[7] Natl Canc Ctr, Goyang, South Korea
[8] VHS Med Ctr, Seoul, South Korea
[9] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea
[10] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[11] Seoul St Marys Hosp, Seoul, South Korea
[12] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol & Oncol, Inchon, South Korea
[13] Seoul Natl Univ Hosp, Dept Clin Pharmacol, Seoul 110744, South Korea
[14] Hanmi Pharmaceut Co Ltd, Seoul, South Korea
[15] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8084
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PREVENTING AND TREATING BRAIN METASTASES WITH THREE FIRST-LINE EGFR-TYROSINE KINASE INHIBITORS IN PATIENTS WITH EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
    Su, Po-Lan
    Wu, Yi-Lin
    Chang, Wei-Yuan
    Lin, Chien-Chung
    Yang, Szu-Chun
    RESPIROLOGY, 2018, 23 : 285 - 285
  • [42] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [43] Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-tyrosine kinase inhibitor (TKI), in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
    Lim, S. M.
    Cho, B. C.
    Han, J. Y.
    Kim, S. W.
    Lee, K. H.
    Nagasaka, M.
    Jo, A.
    Seah, E.
    Kim, C.
    Reungwetwattana, T.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S31 - S32
  • [44] Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Guttman-Yassky, Emma
    Mita, Alain
    De Jong, Maja
    Matthews, Lesley
    McCarthy, Sean
    Iwata, Kenneth K.
    Verweij, Jaap
    Rowinsky, Eric K.
    Krueger, James G.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 2010 - 2019
  • [45] Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure
    Zhou, Juan
    Zhao, Chao
    Zhao, Jing
    Wang, Qi
    Chu, Xiangling
    Li, Jiayu
    Zhou, Fei
    Ren, Shengxiang
    Li, Xuefei
    Su, Chunxia
    Zhou, Caicun
    THORACIC CANCER, 2019, 10 (04) : 957 - 965
  • [46] A phase II study of the HER1/EGFR tyrosine kinase inhibitor (TKI), erlotinib, in Japanese patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy
    Tamura, K.
    Nishiwaki, Y.
    Tamura, T.
    Nakagawa, K.
    Matsui, K.
    Watanabe, K.
    Saijo, N.
    Fukuoka, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 221 - 222
  • [47] Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Ishihara, Mikiko
    Hiyoshi, Yasuhiro
    Kusuhara, Seiichiro
    Nishinarita, Noriko
    Fukui, Tomoya
    Kubota, Masaru
    Sasaki, Jiichiro
    Hisashi, Mitsufuji
    Yokoba, Masanori
    Katagiri, Masato
    Naoki, Katsuhiko
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4883 - 4892
  • [48] EGFR-TYROSINE KINASE INHIBITOR TREATMENT BEYOND PROGRESSION IN LONG-TERM RESPONDERS TO ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER: RELEVANCE OF EGFR MUTATION STATUS
    Faehling, M.
    Eckert, R.
    Kamp, T.
    Straeter, J.
    Ott, G.
    Spengler, W.
    ANNALS OF ONCOLOGY, 2012, 23 : 440 - 440
  • [49] Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
    Gadgeel, Shirish
    Chen, Wei
    Piotrowska, Zofia
    Goldman, Jonathan W.
    Wakelee, Heather
    Camidge, D. Ross
    Varga, Andrea
    Yu, Helena
    Papadimitrakopoulou, Vassiliki
    Nea, Joel
    Soria, Jean-Charles
    Wozniak, Antoinette
    Riely, Gregory
    Narayanan, Vignesh
    Mendenhal, Melody
    Sequist, Lecia
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1263 - S1263
  • [50] RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation
    Yoshida, Tatsuya
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    Goto, Koichi
    LUNG CANCER, 2015, 90 (03) : 477 - 483
12345